Nigeria Dr Uzono Levi and Pharm Adegboyega Adewumi 10 th September 2004 Discussions on Country Plans Presented at the WHO Training Course on Introduction.

Slides:



Advertisements
Similar presentations
Ministry of Labor and Social Policy SOCIAL POLICY COUNCILS Dragica Vlaović-VasiljevićSophia, 2-6th July 2007 Dragica Vlaović-VasiljevićSophia, 2-6th July.
Advertisements

Common/shared responsibilities between jobs.
Sevene E, Mariano A, Mola D Faculty of Medicine / Ministry of Health Pretoria, September 2004 PHARMACOVIGILANCE SYSTEM - MOZAMBIQUE INTRODUCING PV INTO.
HICC An Infection Control Committee provides a forum for multidisciplinary input and cooperation, and information sharing This committee should include.
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
Title: PEOPLE LIVING WITH HIV/AIDSIN EGYPT: ROLE OF COMMUNITY PHARMACIST Authors: Nahla Maher Hegab Pharmacy graduate. Institution: College of pharmacy,
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
Abstract The Knowledge, Perceptions, and Practice of Pharmacovigilance among Community Pharmacists in Lagos State, Southwest Nigeria Oreagba, Ibrahim Adekunle.
COUNTRY ACTION PLAN for INTRODUCING AND IMPLEMENTING A PHARMACOVIGILANCE PROGRAMME IN KENYA Dorine Kagai and Wilfred Oguta Pretoria,2004.
Clinical Science Investigator’s Toolkit: An Evidence Based Practice Resource for the Bedside Nurse Beth Lacoste RN, APRN, CNS, MSN, CCRN Nicole Jones RN-BC,
Regulatory Body MODIFIED Day 8 – Lecture 3.
The Health District Learning objectives What is a health district Why do we focus on the health district What are the tasks of a health district What.
Zambia Pharmacovigilance Action Plan National Plan Revision Proposal Dr Albert Mwango Mrs Bernice MwaleSeptember 2004.
Progress on implementation of Pharmacovigilance in the NATIONAL ARV PROGRAMME November 2009 Dr Mwango A National ARV Programme Coordinator, Ministry of.
Introducing Quality Management in District Hospitals in Tanga Region First Experiences from Korogwe District Hospital.
National Mental Health Programme. Govt of India integrated mental health with other health services at rural level. It is being implemented since 1982.
Entrenching the KNH Formulary to Clinical Practice DR WK SIGILAI MTC CHAIR.
The UN Convention and the National Disability Strategy Eithne Fitzgerald Head of Policy and Public Affairs.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Development of a Road Map to Controlled Substance Diversion Prevention Rene Cronquist, RN, J.D. Director of Practice and Policy Minnesota Board of Nursing.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
PUBLIC HEALTH PROGRAMMES & PHARMACOVIGILANCE Shanthi Pal Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies World.
Pharmacy and Therapeutics Committee
 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
Promoting Rational Drug Use in the Community Developing a country plan.
Training course on Introducing pharmacovigilance into HIV/AIDS programmes Pretoria, South Africa, September 1-10,2004.
Pharmacovigilance in public health programmes Author: Oscar O Simooya, Copperbelt University, Kitwe, Zambia Presented at the training course for introducing.
HEALTH EDUCATION DIVISION MINISTRY OF HEALTH MALAYSIA
Pharmacovigilance in Kenya Dr. Dorine Kagai (NASCOP) Mr. George Muthuri (PPB) Ministry of Medical Services 23 nd November, 2009 ARV PV TRAINING TZ.
Pharmacovigilance Programme of India
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
The policy development for introducing of the oral fluid based rapid HIV test kit in Thailand Writers in the 2009 Write Workshop (WHO Bulletin)
Access to Learning Section E STANDARDS & INDICATORS Council of International Schools New England Association of Schools & Colleges.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Botswana Experience on Public- Private Partnerships Joconiah Chirenda, MD, MPH, MBA Global Business Coalition on.
Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS I Ralph Edwards.
Towards a European network for digital preservation Ideas for a proposal Mariella Guercio, University of Urbino.
OVERVIEW OF THE ZIMBABWE NATIONAL MEDICINES POLICY Dr C E Ndhlovu, M Med Sci, FRCP Chairperson, NMTPAC Deputy Dean, UZCHS National workshop, Jan 22-23,
Pharmacy and Poisons Board Pharmacy and Poisons Board, Kenya Role of Regulation in Optimizing Medicine use KNH/UON Pharmacy Symposium Optimizing Medicine.
HELLEN A. WERE HEALTH ECONOMICS TRACK 2 ND COHORT UNITID FELLOWSHIP PROGRAM 24/05/2011.
Jordan Food & Drug Administration. Pharmaceutical Policy Studies Workshop RUD Unit Plan for RUD Unit.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.
The Health District Learning objectives What is a health district Why do we focus on the health district What are the tasks of a health district What.
Christo van Niekerk, M.D. Senior Director, Clinical Development Pretoria, South Africa Innovating TB Treatment: Opportunities for Private Sector Engagement.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Regulatory Authority.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
Training course on the Pharmacovigilance of antiretroviral medicines 23 – 28 November 2009 Rationale, Objectives and Expected Outcomes.
Dispensary and Administration Site Information Presentation.
Strengthening SME system for national programmes moving from transmission reduction to elimination phase Cambodia.
Fifth Session of the Islamic Conference of Health Ministers Panel Discussion IV: NGO Involvement in the Improvement of Health Services in OIC Member Countries.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
GUIDELINES FOR ANALYSING, PREVENTING AND DEALING WITH VIOLENCE IN A SCHOOL ENVIRONMENT – THE SLOVENIAN APPROACH MOJCA PUŠNIK.
Minimum requirements for Pharmacovigilance in countries.
PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.
Feasibility of establishing PVC in the Ugandan health system By Juliet & Martin September 2004.
Establishing Effective Hospital Drug and Therapeutics Committees: a situational analysis Ndhlovu C E, Simoyi T National Drug and Therapeutics Policy Advisory.
Delivering research to make patients, and the NHS, better Introduction to the Research Ready Accreditation Kelly Adams, Cross Divisional Support Manager,
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
FUNDAMENTALS OF PUBLIC HEALTH Joseph S Duren Lopez Community & Public Health - HCA415 Instructor: Adriane Niare November 10, 2015.
1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.
1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.
ROLES AND RESPONSIBILITIES OF TFDA ON ADDO PROGRAM
Detection & monitoring of ADR
Lecture : Tasks and Responsibilities in the Management of Healthcare Wastes Which one do you want ? by Dr Mohammed Ali Al Zahrani.
11 viii. Develop capacity for signal detection and causality assessment Multi-partner training package on active TB drug safety monitoring and management.
11 i. Create a national coordinating mechanism for aDSM
Clinical Engineering Lecture (3).
National Cancer Center
11 iii. Define management and supervision roles and responsibilities
Presentation transcript:

Nigeria Dr Uzono Levi and Pharm Adegboyega Adewumi 10 th September 2004 Discussions on Country Plans Presented at the WHO Training Course on Introduction of PVG in HIV/AIDS Programmes At Burgers Park Hotel, Pretoria - RSA

Matthew 3:3 ‘the voice of one crying in the wilderness: Prepare the way of the lord, Make His paths straight –‘the voice of one crying in the wilderness: Prepare the way of the lord, Make His paths straight –

Objective To use the new knowledge that we have got, against the background of what we already know about our systems to suggest what we believe is an implementable Pharmacovigilance systemTo use the new knowledge that we have got, against the background of what we already know about our systems to suggest what we believe is an implementable Pharmacovigilance system

Current systems in Nigeria The Secondary Health facilities are under the State Ministries of health in the various statesThe Secondary Health facilities are under the State Ministries of health in the various states The Primary Health Care Centers are under the Primary Health Care Development Agency – a parastatal under the Federal Ministry of HealthThe Primary Health Care Centers are under the Primary Health Care Development Agency – a parastatal under the Federal Ministry of Health

The Tertiary Health facilities are semi-autonomous but report to the department of Hospital Services of the Federal Ministry of HealthThe Tertiary Health facilities are semi-autonomous but report to the department of Hospital Services of the Federal Ministry of Health The Research Centers (2) are Parastatals under the Federal Ministry of HealthThe Research Centers (2) are Parastatals under the Federal Ministry of Health Current systems in Nigeria

The National AIDS/STI Control Programme is under the department of Public Health of the Federal Ministry of HealthThe National AIDS/STI Control Programme is under the department of Public Health of the Federal Ministry of Health The department of Food and Drugs in the Federal Ministry of HealthThe department of Food and Drugs in the Federal Ministry of Health Current systems in Nigeria

The Drug Control and regulatory body – the national Agency for Food and Drugs Control and Administration is a parastatal under the Federal Ministry of HealthThe Drug Control and regulatory body – the national Agency for Food and Drugs Control and Administration is a parastatal under the Federal Ministry of Health Based on the current plans this will be our ADR CenterBased on the current plans this will be our ADR Center Current systems in Nigeria

The National Agency for Food and Drugs Administration and Control (NAFDAC) - currently spear-heading the PVG System has been able to involve representatives of all these organizations in the planning and development of the guidelines and reporting formsThe National Agency for Food and Drugs Administration and Control (NAFDAC) - currently spear-heading the PVG System has been able to involve representatives of all these organizations in the planning and development of the guidelines and reporting forms Coordination

Organizational and Functional Pharmacovigilance Structure Hospital / Research Centers patient Pharmacy store Manufacturer WHO UMC NASCP(NACA) Expert Safety Review panel PVC/DRA Media

Yes A senior staff of the drug regulatory agency has been trained at UPPSULA, workshops have been held and the PVG System is to be launched today.A senior staff of the drug regulatory agency has been trained at UPPSULA, workshops have been held and the PVG System is to be launched today. This system is feasible in Nigeria.This system is feasible in Nigeria. However to ensure that reports begin to be generated as soon as possible a few modification may be necessaryHowever to ensure that reports begin to be generated as soon as possible a few modification may be necessary

“Ready to Go” approach The approach is to identify the facilities already providing ARVs, carry out proper orientation and training for these facilities and commence reporting of ADRs.The approach is to identify the facilities already providing ARVs, carry out proper orientation and training for these facilities and commence reporting of ADRs. Currently 25 ARV CentersCurrently 25 ARV Centers

Non-Government / Private facilities Providing ART Desktop mapping to identify these facilities for inclusion into the PVG programme, e.g State Governments, Missionary Hotels, NGO Support Facilities.Desktop mapping to identify these facilities for inclusion into the PVG programme, e.g State Governments, Missionary Hotels, NGO Support Facilities.

Why should drugs be monitored? To ascertain if drugs on the market fulfill their intended roles in the society.To ascertain if drugs on the market fulfill their intended roles in the society. Drug monitoring is conducted to ensure that adverse reaction or event not discovered through clinical trials are detected with the aim to preventing such reactions/events.Drug monitoring is conducted to ensure that adverse reaction or event not discovered through clinical trials are detected with the aim to preventing such reactions/events.

What should be monitored? All drugs will be monitored for adverse reactions or events.All drugs will be monitored for adverse reactions or events. This allows for comparison of reporting rates among different therapeutic classes of medicines.This allows for comparison of reporting rates among different therapeutic classes of medicines. Investigate all suspected ADRs.Investigate all suspected ADRs. Reports to investigate

Who should monitor? The Pharmacovigilance Centers in collaboration with the reporting centers, manufacturing companies and other stakeholders.The Pharmacovigilance Centers in collaboration with the reporting centers, manufacturing companies and other stakeholders.

Roles and Responsibilities Pharmacovigilance Centers- Identify what to monitorIdentify what to monitor Identify expert and stakeholders who will participate in evaluationIdentify expert and stakeholders who will participate in evaluation Design protocol for the monitoring.Design protocol for the monitoring. Develop budget and Identify possible source of funding.Develop budget and Identify possible source of funding. Provide supervision.Provide supervision.

Roles and Responsibilities Reporting Centers- Design the relevant studies.Design the relevant studies. Carryout the studyCarryout the study Present the report of study to the PV Center.Present the report of study to the PV Center. Manufacturing Companies- Collaborate with the PV Center and the reporting centers to design and carry out monitoring.Collaborate with the PV Center and the reporting centers to design and carry out monitoring.

Roles and Responsibilities Experts and other stakeholders e.g. PLWHA - Provide necessary advice and support.

What to Report The basic issue for us will be the need to create a notification culture We recommend reporting of all suspected ADR known or not, serious or not.

Need for Special Investigation Teams The PGV Center should have a team that is capable of carrying out the initial confirmation of information's and reports These reports can then be sent to experts for review and the experts meet to discuss, arrive at a conclusion and make recommendations.

Reporting Flow Based on the current plans the current reporting approach is what is being adopted for Nigeria With more experience, we believe that the system will be adjusted to produce better results.

Printing of Forms Duplicate -The reporter keeps a copy -The other copy to the PVG Center

How Should Monitoring Occur Spontaneous MonitoringSpontaneous Monitoring Cohort studiesCohort studies RegistriesRegistries

When should you be encouraging reporting?

Reports Timelines -Initial Report – Immediately (24hr) -Investigation report – Depends (1wk) -Aggregate Reports – 1 month All reports should be submitted to the National Coordinator. All reports should be investigated

How do you manage non- serious ADRs / Should you encourage reporting of serious events/reactions only or include non-serious as well

Resources Available Human Resources -A good number of trained health workers Infrastructures -Health Facilities in every state / Local Government areas -Centers of Excellence and research Centers Funding – Government/Global Funds –Donor funds

Critical Success Factors Awareness of pharmacovigilance system within informal sector -Community & religious leaders, Shopkeepers, traditional healers, community health workers and school teachers Quality control of laboratories

Critical Success Factors Literacy of reporters Clearly defined responsibilities Adequate training and education Open communication between public health care providers and policy makers Judicious and proactive use of the media, professional and general public Good Coordination